Evaluation of topical tranexamic acid effectiveness in the treatment of melasma

Evaluation of topical tranexamic acid versus oral tranexamic acid in the treatment of melisma: a randomized, double-blind clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181208041882N9

Enrollment

Registered

2023-10-09

Start date

2022-05-20

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma. Chloasma

Interventions

Intervention 1: Intervention group: Patients with melasma use Tranexamic acid capsules 250 mg orally twice a day for 8 weeks. Intervention 2: Intervention group: Patients with melasma use 5% tranexami

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Women with melasma from 18 to 60 years MMASI score greater than 8.5 Do not use oral contraceptives The patient has not received medication to treat melasma in the last three months

Exclusion criteria

Exclusion criteria: Drug allergy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Evaluation of of melasma improvement. Timepoint: Weeks 0, 4, 8. Method of measurement: MASI ( Melasma Area Severity Index) Score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Heydari

Yazd University of Medical Sciences

b.heydari@ssu.ac.ir+98 35 3820 3410

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026